This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for…
The post Biosimilar Naming: Distinguishable or Disingenuous? appeared first…
Biosimilar Naming: Distinguishable or Disingenuous? Read Post »
How to Order the FDA Orange Book Historical copies of the FDA Orange Book archives are very potent tools for scholarly research and for litigation support, but until now there…
The post Download FDA Orange Book Archives appeared first on DrugPatentWatc…
Dana Goldman, Anupam Jena, Posted with permission from STAT It’s hard not to like the notion of value-based pricing for prescription drugs. It aims to ensure that the prices we pay for…
The post Value-based drug pricing makes sense, but is difficult to…
Value-based drug pricing makes sense, but is difficult to pull off Read Post »
One of the hottest-button political issues of the day is high prescription drug costs. On one side of the debate are politicians and patient groups espousing a populist viewpoint seeking…
The post The Cost Of A Cure: Patent Rights And Drug Prices appea…
The Cost Of A Cure: Patent Rights And Drug Prices Read Post »
Ed Silverman, Posted with permission from STAT Shortly before his company won the right last week to sell a new drug for severe eczema, Dr. Len Schleifer made a brash…
The post How a $37,000-a-year medicine sets a good model for drug pricing appeared f…
How a $37,000-a-year medicine sets a good model for drug pricing Read Post »
Rebecca Robbins, Posted with permission from STAT Plus When drug and device makers need a new chief medical officer or vice president, they often start by turning to executive recruiters. One…
The post Q&A: Three big mistakes drug companies make in rec…
Q&A: Three big mistakes drug companies make in recruiting new employees Read Post »
Damian Garde, Posted with permission from STAT Has the age of the biotech blockbuster come to a close? Over the past year, a string of would-be best-sellers, expected to generate…
The post As blockbuster drugs fizzle, biotech looks warily to the next b…
As blockbuster drugs fizzle, biotech looks warily to the next big thing Read Post »
File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food and Drug Administration recently released for naming both biologic medicines…
The post Americans overspend $73bn on bran…
By Dylan Scott, Posted with permission from STAT Mark Cuban has something to say about prescription drug prices. The billionaire entrepreneur and Dallas Mavericks owner might not seem like an…
The post Mark Cuban Sounds Off on Drug Prices appeared fir…
What’s in a name? An awful lot when it comes to biosimilars. A newly released survey suggests variations in how biosimilars are named may affect the willingness of pharmacists to…
The post Biosimilar names may affect pharmacist dispensing habits appear…
Biosimilar names may affect pharmacist dispensing habits Read Post »
Get new actionable insights and updates from BiotechBlog
